Roles of Nitric Oxide in Surgical Infection and Sepsis

Mark L. Johnson, M.D., Timothy R. Billiar, M.D.

Department of Surgery, A1010, University of Pittsburgh Medical Center, Presbyterian University Hospital, 200 Lothrop Street, Pittsburgh, PA 15213, USA

Abstract. Recent advances in nitric oxide (NO) research have begun to elucidate the roles of NO in sepsis and infection. Although adequate levels of NO production are necessary to preserve perfusion and carry out cytoprotective functions in sepsis, overproduction appears to contribute to hemodynamic instability and tissue damage. These observations have led to the development of strategies to inhibit NO synthesis or scavenge excess NO in patients with septic shock. Local expression of the inducible NO synthase also has antimicrobial functions. The combination of NO with superoxide forms peroxynitrite which participates in bacterial killing in the peritoneal cavity. The capacity of red blood cells and hemoglobin to remove NO most likely accounts for the adjuvant effect of blood in peritonitis.

This review will summarize the pathobiology of NO in surgical sepsis and infection.

Often in biology the most complex processes are governed by the simplest of mediators. Such is the case for sepsis, where bacterial endotoxin (lipopolysaccharide; LPS), cytokines, and other small biologically active molecules initiate and propagate the cascade of events that culminate in unrelenting hypotension, multiple organ dysfunction, and frequently death. Nitric oxide (NO), one of the smallest synthetic products of mammalian cells, has leapfrogged forward as an important contributor to the physiology and pathophysiology of sepsis. This review explores the diverse roles this mediator plays in clinical conditions familiar to surgeons: surgical infections and sepsis.

Biochemistry of Nitric Oxide

Furchgott and Zawadzki first made the observation in 1980 that endothelium was required for vascular smooth muscle relaxation in response to acetylcholine [1]. Seven years later Palmer et al. [2] and Ignarro et al. [3] identified NO as this endothelial-derived relaxing factor. Since then, NO has proved to be one of nature’s most utilized and interesting molecules, with involvement in such diverse physiologic processes as neurotransmission, vascular tone, sphincter relaxation, microbial killing, and penile erection. Nitric oxide is a relatively unstable, uncharged free radical. Its small size, absence of electrical charge, and lipophilic nature allow it readily to diffuse across cell membranes; although its short half-life (seconds) in aqueous, oxygenated solutions limits its effects to the local environment. Either NO or its reaction products target an abundance of molecular targets, including heavy metals, other radicals, and protein thiol groups. Through these interactions, NO modifies protein function and leads to or protects from cellular damage. NO oxidizes rapidly in the presence of oxygen or hemoglobin to form the measurable end-products nitrite and nitrate.

Nitric oxide is synthesized from the amino acid l-arginine via a family of enzymes termed nitric oxide synthases (NOS). Named for the cell type where they were first discovered, there are now three known isoforms of NOS—neuronal (nNOS, NOS1), inducible (iNOS, NOS2), and endothelial (eNOS, NOS3)—each encoded by different genes (Table 1). Further study revealed that expression of all three isoforms is not limited to a single cell type. Two of these forms, endothelial and neuronal NOS, are constitutively expressed under normal conditions and are collectively called cNOS (reviewed in [4]).

All NOS enzymes catalyze the five-electron oxidation of the guanidino nitrogen of l-arginine to citrulline (Fig. 1), possess a protochlorophyl IX heme group, exist as homodimers, and are active only in the presence of cofactors nicotinamide adenine dinucleotide phosphate (NADPH), flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN), and tetrahydrobiopterin (H4B).

iNOS differs from the cNOS isoforms in both regulation of activity and expression. The cNOS enzymes are typically always present in cells, and their activity is regulated by intracellular calcium levels through a calcium/calmodulin-dependent mechanism. The binding of acetylcholine, bradykinin, histamine, and other vasoactive substances to endothelial cells results in a receptor-mediated calcium influx. Calcium binds the cytosolic calcium-binding protein calmodulin, which transiently binds cNOS, increasing NO production. NO then diffuses across cell membranes into adjacent smooth muscle cells, where it activates guanylate cyclase. Increased production of cyclic guanosine monophosphate (cGMP) activates cGMP-dependent protein kinases, ultimately leading to vasorelaxation. As intracellular calcium levels decrease, the stimulus for NO production is eliminated. In a similar manner, neurons expressing nNOS respond to excitatory amino acid stimulation by increasing NO production and increasing cGMP levels.

iNOS protein, as its name implies, is typically not present in
unstimulated mammalian cells but is synthesized de novo in response to stimuli such as endotoxin or inflammatory cytokines such as tumor necrosis factor-α (TNFα), interleukin-1 (IL-1), and interferon-γ (IFNγ) [5, 6]. Hence there is a necessary time delay between stimulation and NO formation. Once formed, iNOS produces much higher quantities of NO and is maintained tonically active by a permanently bound calmodulin found in each subunit of the iNOS homodimer [7]. iNOS-mediated NO production is limited only by the concentration of enzyme and the availability of substrate and cofactors.

The potential for NO to participate in myriad physiologic processes is apparent from the study of its chemistry and regulation. The constitutive isoforms of NOS, with their tightly controlled, intermittent, low-level NO production, combined with the diffusibility of NO make for an ideal autocrine and paracrine messenger. Conversely, the inducible NOS isoform, with its ability to produce larger quantities of NO, allows the body to unleash the reactivity of NO in a variety of responses.

### Molecular Targets

Nitric oxide participates in cellular metabolism, signal transduction, and cellular protection and toxicity by interacting with a variety of cellular components including heavy metals, reactive oxygen species, and biologic molecules such as thiol groups (Fig. 2). One of the most biologically significant aspects of NO is its ability to react with intracellular metals and metal-containing proteins [8]. A prime example is the interaction with the iron heme moiety of guanylate cyclase. In that reaction, NO reacts with heme to liberate a transaxial ligand (histidine), resulting in enzyme activation and cGMP synthesis. In contrast, other heme proteins (e.g., catalase [9, 10] and cytochrome P450 [11]) are inhibited by NO. There is evidence to suggest that NO interacts with the heme prosthetic group of cyclooxygenase to either activate or inhibit the enzyme [12–14]. NO rapidly reacts with heme groups in hemoglobin and myoglobin to form iron nitrosyl hemoprotein, which may attenuate NO-mediated biologic functions [15, 16], as hemoproteins such as hemoglobin and myoglobin are the most powerful biologic scavengers for NO. NO can even regulate its own biosynthesis by reacting with the heme iron in both eNOS and iNOS [17–19]. This feedback inhibition may serve to control neurotransmitter release, endothelium-dependent relaxation, and NO-mediated cytotoxicity.

Nitric oxide also mediates cellular events by reacting with enzymes containing nonheme iron [20]. Such enzymes include mitochondrial cis-aconitase [21, 22], complexes I and II of the mitochondrial electron transfer chain [23–25], and ribonucleotide reductase [26, 27]. Through these interactions NO may inhibit cellular adenosine triphosphate (ATP) and DNA synthesis.

*S-Nitrosylation of intracellular nucleophile thiol groups by NO, or more likely NO products (e.g., nitrosonium, NO⁺), activated by reaction with heavy metals or other radicals [8, 28] represents a newly discovered cell signaling mechanism and can regulate protein function in several ways (reviewed in [29]). Activation of calcium-dependent potassium channels in vascular smooth muscle

---

**Table 1. Nitric oxide synthase isoforms.**

| NOS isoform | Alternate name | NOS expression | NO production | Function/actions |
|-------------|----------------|----------------|---------------|----------------|
| Type I      | Neuronal NOS   | Mostly constitutive | Small, intermittent | Neurotransmission, Cell signaling, Neurotoxicity |
| Type II     | Inducible NOS  | Usually requires induction | Large, sustained | Cytoprotection, Cytotoxicity, Antimicrobial Immuno-regulation |
| Type III    | Endothelial NOS| Constitutive | Small, intermittent | Cell signaling, Vasomotor tone regulation |

NOS: nitric oxide synthase.
is mediated by a conformational change following S-nitrosylation [30]. The cytosolic glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is inhibited by nitrosylation of thiol groups located within the active site [31]. S-Nitrosothiols may also serve as a reservoir for NO [8,32–35]. Jia et al. [36] suggested that S-nitrosylated hemoglobin functions as a NO carrier, contributing to both efficient oxygen delivery and distant vasomotor control.

As previously stated, NO reacts with oxygen radical species to yield a multitude of secondary products, some of which are more reactive and toxic than NO [37]. In many pathologic conditions, such as inflammation and endotoxemia, NO and superoxide anion (O2−) are produced simultaneously. The reaction of NO with O2− to form peroxynitrite (ONOO−), a much stronger oxidant than either NO or O2−, has clear toxicologic significance [38,39]. NO and O2− form ONOO− at near diffusion-controlled rates (k = 6.7 × 107 M−1 sec−1) [40]. This reaction is fast enough to compete with superoxide dismutase (SOD) when elevated levels of NO are present. Protonation of ONOO− yields peroxynitrous acid (ONOOH), pKa = 6.8) [41], which decomposes to nitrogen dioxide (NO2) and an oxidant with hydroxyl radical-like (OH) activity [38].

Cytotoxicity of Nitric Oxide

Although enzyme inhibition or toxic radical formation may explain NO-mediated control of target cell growth, whether they be microorganisms, tumor cells, or invading lymphocytes, the nonselective action of NO overproduction also undoubtedly explains some of its local cytotoxicity. Peroxynitrite inflicts cellular damage through lipid peroxidation [65], oxidation of sulfhydryl groups [41], nitration of tyrosine residues [28], and oxidation of cellular antioxidants [66,67]. It has also been implicated in inactivation of the manganese/iron SOD [28]; it also may explain NO-mediated inactivation of aconitate [68,69] and the mitochondrial electron transport chain [70]. NO or other reactive nitrogen intermediates can induce mutagenesis by deaminating purine and pyrimidine DNA bases or inducing DNA strand breaks [71–74]. Furthermore, by inducing DNA strand breaks, NO (or more likely peroxynitrite) activates the nuclear repair enzyme poly(ADP-ribose)polymerase (PARP). PARP activation results in a futile energy-consuming cycle, depleting intracellular NAD+, thereby inhibiting glycolysis and ATP synthesis [75–77]. Szabó et al. have suggested that ONOO− activation of PARP may explain the energetic depletion of vascular smooth muscle cells and circulatory failure seen during sepsis [78,79].

Lastly, in contrast to observations that NO blocks apoptosis, others have found that NO induces programmed cell death. Postulated mechanisms include p53 induction or oxidant DNA damage [80–82].

Role of NO in Inflammation and Infection

Through tissue damage, NO or ONOO− promotes inflammatory changes, but there is also evidence that NO may regulate and promote inflammatory cytokine synthesis independent of tissue injury. NO enhances TNFα and IL-8 release [83,84] and activates cyclooxygenase, increasing formation of proinflammatory prostaglandins [13]. Conversely, NO may also play an antiinflammation role. NO reduces neutrophil oxidant production by inactivating neutrophil NADPH oxidase [85,86], and it appears to downregulate cytokine production, as NO inhibition increases IL-6 and TNF release and increases mortality after endotoxin challenge [87,88]. Pretreatment with small doses of LPS protects animals from a second lethal endotoxin challenge, but pretreatment with the nonspecific NOS inhibitor L-N-methyl-L-arginine (L-NMA) abolished this protection, suggesting that NO upregulates immunity [89].

Nitric oxide appears to be part of the adaptive response to infection. It exerts antimicrobial activity against an expanding list of bacteria, parasites, fungi, and viruses (reviewed in [90]) [90–93]. NO is an important part of the macrophage arsenal, as inhibition of NO synthesis diminishes both microbial and tumoricidal activity [23]. Intracellular parasites are particularly sensitive to NO [94–96].

Several authors have postulated potential mechanisms for NO-mediated microbial killing. NO is the major molecule responsible for cytotoxicity of Entamoeba histolytica and may function via a superoxide-associated mechanism [97]. Host resistance to Legionella pneumophila may relate to IFNγ-mediated iNOS induction [98]. ONOO−, not NO, may be the functional bactericidal agent [99] that kills Escherichia coli in concentrations achievable by activated macrophages [39]. Rubbo et al. further found that...
poxynitrite inactivates succinate dehydrogenase and NADH-fumarate reductase (via interaction with critical sulfhydryl residues), thereby inhibiting cellular respiration in Trypanosoma cruzi epimastigotes [100].

**NO in Bacterial Peritonitis**

Although the surgical world has long recognized the adjunctive effect of erythrocytes (RBCs) and hemoglobin on mortality in experimental bacterial peritonitis, the mechanisms for this observation were not clear for years [101, 102]. Erythrocytes have several antioxidant systems, including SOD, catalase, glutathione, glutathione reductase, and heme. RBCs can inhibit the oxidative bactericidal mechanism in superoxide-generating systems [103, 104]. Erythrophagocytosis can inhibit macrophage antibacterial function and oxidative bactericidal mechanisms [105, 106]. RBCs and hemoglobin have also been implicated in NO scavenging in vitro and in vivo [15, 107]. All of these points suggest that erythrocytes increase mortality associated with peritonitis by scavenging both reactive oxygen intermediates (ROIs) and NO, thereby quenching the microbicidal properties of these species.

Our group recently confirmed this hypothesis [108]. Peritoneal injection of live bacteria (E. coli) resulted in high levels of \( \text{O}_2^- \) and NO production. iNOS was strongly expressed in the leukocytes entering the peritoneal cavity in response to this infection. Administration of either RBCs or a combination of SOD, catalase, and L-NAME with a sublethal dose of live bacteria significantly increased intraperitoneal bacterial counts and mortality while reducing NO, \( \text{O}_2^- \), and ONOO⁻ formation. Thus although RBCs may protect cells and tissues from injury, peritoneal contamination protects bacteria from the oxidative bactericidal activity of the host defense system by scavenging \( \text{O}_2^- \) and NO in the peritoneal cavity (Fig. 3).

**NO in Septic Shock**

It is now clear that NO contributes to the pathophysiology of sepsis. NO synthesis is enhanced after exposure to endotoxin [109, 110] and the sepsis-associated cytokines IL-1β, TNFα, and IFNγ [5, 6]. Also, several investigators have demonstrated increased production of NO degradation products in patients with sepsis [111–114] and following cytokine immunotherapy for cancer [115, 116].

**Role of NO in Hemodynamic Changes in Sepsis**

A cardinal feature of septic shock is profound hypotension poorly responsive to fluid resuscitation and vasopressor therapy. NO overproduction may be an important contributor to this hypotension, as NO inhibition increases blood pressure in animals challenged with endotoxin [117–120], TNF [121], IL-1 [122], and IL-2 [123] (reviewed in [124]). Although the nonselective NOS inhibitor L-NAME increases blood pressure in normal animals as well, the hypertensive effect is much greater in septic animals. Loss of vascular reactivity after endotoxin exposure also involves NO [125–128], as NO inhibition improves the hyporeactive response to vasopressors seen with sepsis [129–131].

One potential discrepancy when attributing the hypotension of sepsis to increased NO production is the observation that induction of iNOS requires a 3- to 4-hour time delay before appreciable increases in NO production [132]. Some investigators have addressed this issue by noting that several septic mediators, although inducing formation of iNOS, also up-regulate constitutive NO synthesis [110, 124, 133]. Hence the hypotension noted shortly after endotoxin or TNF exposure is probably due to increased cNOS activity. Mechanisms of cNOS activation are unclear but may relate to LPS-induced release of a variety of mediators (bradykinin, histamine) that increase NO release from the endothelium (reviewed in [132]).

Nitric oxide is implicated in the cardiac dysfunction seen with septic shock. Inflammatory cytokines cause dose-dependent negative inotropic effects that are blocked by L-NAME treatment. The ameliorating effect of L-NAME can be reversed by adding substrate L-arginine [133, 134]. Thus NO not only may cause excessive vasodilation, it may contribute to decreased cardiac contractility.

**Therapeutic Interventions**

Therapeutic agents targeting individual mediators in the septic cascade have largely failed to show significant benefit in terms of mortality [135]. Most recently, several researchers have explored NO as a potential target for therapeutic manipulation (reviewed in [136]). As previously mentioned, NO inhibitors cause an immediate rise in blood pressure and vascular resistance. However, administration of excessive doses of NO inhibitors that are not selective for the inducible isoforms of NO also cause concomitant inhibition of eNOS and may increase the incidence of organ ischemia, microvascular thrombosis, and mortality [45, 48, 137]. A fall in cardiac output below normal levels has been reported in septic dogs and pigs treated with NO inhibitors [49, 117, 138] but may relate to dosing and nonspecific NOS inhibition.
Survival studies using NOS inhibitors have not identified a clear effect. NOS inhibition increases mortality in several septic animal models [50, 87, 139–141]. Evans et al. concluded that NOS inhibition has no effect on survival [142], whereas, others have suggested that NOS inhibition improves survival [143, 144].

Maintenance of vascular perfusion by cNOS appears to play a protective role against acute shock and could explain the deleterious actions of NOS inhibition administered early in shock models. Early administration of nonspecific NOS inhibitors L-NAME or L-NMA results in widespread organ damage, whereas late administration after endotoxin reduces toxicity. This finding suggests that initial suppression of cNOS following LPS challenge aggravates injury, whereas delayed inhibition of iNOS provides protection against subsequent damage [137, 145–148].

Noting the conflicting results of inhibitor studies, Nava et al. [144] suggested that high-dose NOS inhibition could impair both constitutive and inducible NOS, effectively removing all NODependent vasodilatory tone. This reaction in the presence of circulating sepsis-induced vasoconstrictors, may lead to fatal dependent vasodilatory tone. This reaction in the presence of constitutive and inducible NOS, effectively removing all NO-protection against subsequent damage [137, 145–148].

Consistent with these observations, more specific iNOS inhibition has shown promising therapeutic potential. Aminoguanidine, a relatively selective iNOS inhibitor, decreases bacterial translocation after high-dose endotoxin challenge perhaps by reducing intestinal damage [150]; and it attenuates the delayed circulatory failure and mortality in endotoxemia models [151]. S-Methylisothiourea sulfate, a potent and relatively selective iNOS inhibitor, reverses hypotension and vasoconstrictor hyporeactivity caused by endotoxin while attenuating liver and renal injury and improving survival [152]. iNOS-specific NOS inhibition might reduce the circulatory failure and tissue toxicity associated with excessive NO production without the consequences of CNOS inhibition.

The successful administration of NOS inhibitors in septic patients has already been reported [153–156]. Petros et al., in the first human trial, treated two patients with septic hypotension unresponsive to high-dose norepinephrine with L-NMA and L-NAME (in one patient) and noted rapid increases in blood pressure and vascular resistance with clinical improvement in both patients, one of whom went on to survive [153]. This group then performed a randomized, double-blind trial where 12 patients received L-NMA bolus injections followed by constant infusion. Injections increased systolic and diastolic blood pressure and systemic and pulmonic vascular resistance while decreasing hyperdynamic cardiac output toward normal levels. They concluded that NO overproduction contributes to septic vasodilation, and that inhibition may be therapeutic [156].

Generalizations from animal studies to potential human interventions are limited for several reasons. Important species differences exist. NOS inhibitor doses used in animal studies have generally been much larger than those used in humans. The proper dose of NOS inhibitor is still not established, nor is the appropriate timing for NOS inhibition. The nonspecific nature of clinically available inhibitors also limits their widespread application.

The inability to create a highly selective iNOS inhibitor has led researchers to explore other means of elucidating the relative contributions of iNOS and cNOS to inflammation. The embryonic disruption of the iNOS gene in mice has led to mice that do not express iNOS protein (iNOS knockouts). They display similar growth rates, behavior, and reproduction as control mice. They do not, however, show increased nitrite and nitrate synthesis after endotoxin stimulation [157–159]. Survival studies using high doses of endotoxin have revealed conflicting results in these mice. Laubach et al. found no significant survival differences between iNOS knockout and wild-type mice [159]. MacMicking et al. made the contrasting observation that anesthetized knockout mice were significantly protected from moderate-dose endotoxin-induced hypotension and death; but only at high doses of endotoxin (30 mg/kg) were unanesthetized iNOS knockout mice protected [157]. In contrast, Wei et al. [158] found that iNOS knockout mice were indeed protected from intraperitoneal endotoxin challenge. The discrepancies in these early observations have not been adequately explained. iNOS may play a more subtle role than survival from overwhelming doses of endotoxin, or other iNOS-independent death mechanisms may exist.

Other researchers have explored the role of inhaled NO in the treatment of pulmonary disease. Unlike systemic vasodilators but like prostacyclin, inhaled NO reduces pulmonary artery pressure without inducing systemic hypotension. The absence of systemic hemodynamic effects probably reflects the rapid binding and inactivation of NO by hemoglobin. In experimental models of sepsis and oxidant lung injury, pulmonary hypertension, gas exchange, and ventilation-perfusion mismatch are all improved with NO inhalation [160–165]. The mechanism probably involves selective increased perfusion of ventilated alveoli or antiinflammatory effects of NO [166]. Clinical trials of inhaled NO have yielded promising results in patients with severe adult respiratory distress syndrome (ARDS) and pulmonary hypertension [167–169]. Controlled trials of inhaled NO in septic patients are awaiting completion.

Other areas currently being explored to assess the contributions of NO to sepsis include the use of NO scavengers, substrate and cofactor manipulations, the use of site-specific NO donors, and the application of gene transfer technology [170]. The use of NO scavengers that remove only the “excess” NO regardless of source present an attractive approach, especially because it is probable that some iNOS activity is beneficial. Kazmierski et al. have identified iron chelators that scavenge excess NO and protect against a lethal murine model of endotoxic shock [171]. Other approaches are less specific. For example, inhibition of synthesis of the NOS cofactor tetrahydrobiopterin reduces NO production and partially ameliorates endotoxin-induced hypotension in rats [172]. Methylene blue, which does not affect NOS but does inhibit guanulate cyclase, improves blood pressure and cardiac function in septic patients [173, 174].

Methods to support NO availability suggest that a relative NO deficiency may exist at certain intervals or specific anatomic sites during sepsis. For example, dietary arginine supplementation
improves survival in animal models of sepsis perhaps by preventing intestinal damage and bacterial translocation [175]. Also, NO donors attenuate endotoxin-induced intestinal damage and hemodynamic abnormalities, suggesting that an appropriate level of NO availability may be beneficial during sepsis [176, 177].

Conclusions
A review of the literature exploring the role of NO in sepsis reveals several paradoxes. NO appears to be both cytoprotective and cytotoxic. NO appears to block and induce inflammation. NOS inhibitors improve hemodynamics and reduce organ injury, although other researchers have insisted that NOS inhibitors are detrimental, reducing cardiac performance, worsening oxygenation, and hastening demise.

One answer to the NO paradox involves the use of multiple experimental models. High-dose NOS inhibition, with impairment of both the cNOS and iNOS isoforms, routinely results in tissue damage and deleterious outcomes, whereas lower-dose and more specific iNOS inhibition tends to have protective effects. As we take advantage of the pharmacologic developments of more selective inhibitors of iNOS, as we become more familiar with dosage and timing variables, and as other tools (e.g., genetically manipulated mice) become available, we may further define the role of NO and the NO synthase isoforms and thus effect some therapeutic benefit.

On the other hand, it is not surprising that a molecule with such diverse chemical capabilities can have such divergent effects. At physiologic concentration, NO is protective; it provides necessary vasodilation, inhibits platelet and leukocyte aggregation, and participates in both protein modification and local and perhaps distant cell signaling via nitrosothiol formation. But during pathologic conditions, overexpression exposes the environment to its toxic potential with toxic radical formation, protein inhibition, and DNA damage. Complete inhibition may not be desirable. Inadequate or excessive NO production is ultimately harmful to the host, resulting in hypercoagulability, altered perfusion, uncontrolled infection, tissue injury, and hypotensive shock. Appropriate amounts of NO as a part of the inflammatory response result in host survival. The effect of NO therefore depends on the rate and duration of NO formation, the presence of reactive substrates and the cell-specific response to the presence of NO.

Résumé
Certsains progrès récents dans la recherche du monoxyde d’azote (MO) semblent indiquer le rôle que ce composé joue dans l’infection et le sepsis. Bien qu’un certain niveau de production de MO soit nécessaire pour conserver la perfusion et accomplir les fonctions de cytoprotection dans le sepsis, la surproduction de MO apparaît comme un facteur d’instabilité hémodynamique et de lésions tissulaires. Ces observations ont amené à développer des stratégies thérapeutiques pour inhiber la synthèse de MO ou éliminer le MO en excès chez le patient en choc septique. L’expression locale de l’enzyme MO synthase indiscutable a également des répercussions sur les fonctions antimicrobiennes. La combinaison de MO avec la superoxyde est responsable de la formation de peroxydinitrite qui participe à la mort bactérienne dans la cavité péritonéale. La capacité des globules rouges et de l’hémoglobine à extraire le MO rend compte sans doute de l’effet adjuvant du sang dans la cavité péritonéale. Dans cette revue, on résume la pathobiologie de le MO dans le sepsis en chirurgie et l’infection.

Resumen
Los recientes avances en la investigación del óxido nítrico (ON) aportan claridad sobre su papel en la sepsis y la infección. Aunque en la sepsis se requieren niveles adecuados de producción de ON para preservar la perfusión y cumplir las funciones citoprotectoras, la producción exagerada parece contribuir a la inestabilidad hemodinámica y al daño celular. Tales observaciones han dado lugar al desarrollo de estrategias tendientes a inhibir la síntesis de ON y la remoción de su exceso en pacientes en shock séptico. La expresión local de la sintasa inducible del ON también posee funciones antimicrobianas. La combinación de ON con superóxido forma peroximetrito, el cual participa en la eliminación bacteriana de la cavidad peritoneal. Muy probablemente la capacidad de los eritrocitos y de la hemoglobina para remover ON explica el efecto coadyuvante de la sangre en la peritonitis. En el presente artículo se resume la patobiología del ON en las sepsis y la infección quirúrgica.

Acknowledgments
This work was supported by NIH grant R01-GM-44100. T.R.B. is the recipient of the George H.A. Clowes Jr., M.D., F.A.C.S. Research Career Development Award of the American College of Surgeons.

References
1. Furchgott, R.F., Zawadzki, J.V.: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288:373, 1980
2. Palmer, R.M.J., Ferrige, A.G., Moncada, S.: Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327:524, 1987
3. Ignarro, L.J., Buga, G.M., Wood, K.S., Byrns, R.E., Chaudhuri, G.: Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. U.S.A. 84:9265, 1987
4. Nathan, C.F., Xie, Q.: Nitric oxide synthases: roles, tolls, and controls. Cell 78:915, 1994
5. Nathan, C., Xie, Q.W.: Regulation of biosynthesis of nitric oxide. J. Biol. Chem. 269:13725, 1994
6. Morris, S.M., Billiar, T.R.: New insights into the regulation of inducible nitric oxide. Am. J. Physiol. 266:E829, 1994
7. Cho, H.J., Xie, Q.W., Calaycay, J., Mumford, R.A., Swiderek, K.M., Lee, T.D., Nathan, C.: Calmodulin is a subunit of nitric oxide synthase from macrophages. J. Exp. Med. 176:599, 1992
8. Stamler, J.S., Singel, D.J., Loscalzo, J.: Biochemistry of nitric oxide and its redox-activated forms. Science 258:1898, 1992
9. Kim, Y.M., Bergonia, H.A., Muller, C., Pitt, B.R., Watkins, S.C., Lancaster, J.R., Jr.: Loss of degradation of enzyme-bound heme induced by cellular nitric oxide synthetase. J. Biol. Chem. 270:5710, 1995
10. Brown, G.C.: Reversible binding and inhibition of catalase by nitric oxide. Eur. J. Biochem. 232:188, 1995
11. Müller, C.M., Scierka, A., Stiller, R.L., Kim, Y.M., Cook, D.R., Lancaster, J.R., Jr., Buffington, C.W., Watkins, W.D.: Nitric oxide mediates hepatic cytochrome P450 dysfunction induced by endotoxin. Anesthesiology 84:1435, 1996
12. Corbett, J.A., Kwon, G., Turk, J., McDaniel, M.L.: IL-1 beta induces the coexpression of both nitric oxide and cyclooxygenase by islets of...
22. Stuehr, D.J., Nathan, C.F.: Nitric oxide: a macrophage product
21. Hibbs, J.B., Jr., Vavrin, Z., Taintor, R.R.: L-Arginine is required for
differentiation of murine macrophages
20. Nathan, C.: Nitric oxide as a secretory product of mammalian cells.
19. Buga, G.M., Griscavage, L.M., Rogers, N.E., Ignarro, L.J.: Inducible
nitric oxide synthase from a rat alveolar macrophage cell line is
inhibited by nitric oxide. J. Immunol. 151:6329, 1993
18. Buga, G.M., Griscavage, L.M., Rogers, N.E., Ignarro, L.J.: Negative
feedback regulation of endothelial cell function by nitric oxide. Circ.
Res. 73:808, 1993
17. Griscavage, J.M., Rogers, N.E., Sherman, M.P., Ignarro, L.J.: Inducible
nitric oxide synthase from a rat alveolar macrophage cell line is
inhibited by nitric oxide. J. Immunol. 151:6329, 1993
16. Fisch, C., Robin, M.A., Letteron, P., Fromenty, B., Berson, A.,
Renault, S., Chachaty, C., Pessayre, D.: Cell-generated nitric oxide
inactivates rat hepatocyte mitochondria in vitro but reacts with
reagents in vivo. Gastroenterology 110:210, 1990
15. Lancaster, J.R., Jr.: Simulation of the diffusion and reaction of
endogenously produced nitric oxide. Proc. Natl. Acad. Sci. U.S.A.
91:8137, 1994
14. Kanner, J., Harel, S., Granit, R.: Nitric oxide, an inhibitor of lipid
oxidation by lipoxygenase, cytochrome c and hemoglobin. Lipids
27:46, 1992
13. Salvemini, D., Misko, T.P., Masferrer, J.L., Seibert, K., Currie, M.G.,
Needleman, P.: Nitric oxide activates cyclooxygenase enzymes. Proc.
Natl. Acad. Sci. U.S.A. 90:7240, 1993
12. Johnson and Billiar: Nitric Oxide and Sepsis
11. Seres, G., Szabo, C.: Inhibition of purine nucleotide reductase by
macrophage-derived nitric oxide. Arch. Biochem. Biophys. 327:461,
1996
10. Singel, D., Kirk, M., Freeman, B.A.: Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc. Natl. Acad. Sci. U.S.A. 87:1620, 1990
9. Birnbaum, D., Ramsay, W.L., Gershengorn, M.C., Kubes, P., Granger, D.N.: Nitric oxide modulates microvascular interactions of nitric oxide. Cell 116:149, 1994
8. Robertson, F.R., Offner, P.J., Ciceri, D.P., Becker, W.J., Pruitt, B.A., Jr.: Detrimental hemodynamic effects of nitric oxide synthase inhibition in septic shock. Arch. Surg. 129:149, 1994
7. Minnard, E.A., Shou, J., Naama, H., Cech, A., Gallagher, H., Daly, J.M.: Inhibition of nitric oxide synthesis is detrimental during endotoxemia. Arch. Surg. 129:142, 1994
6. Martin-Sanz, P., Diaz-Guerra, M.J., Casado, M., Bosca, L.: Bacterial lipopolysaccharide antagonizes transforming growth factor beta 1-
induced apoptosis in primary cultures of hepatocytes. Hepatology 23:1200, 1996
57. Chun, S.Y., Eisenhauer, K.M., Kubo, M., Hsueh, A.J.: Interleukin-1 beta suppresses apoptosis in rat ovariian follicles by increasing nitric oxide production. Endocrinology 136:3120, 1995
58. Radomski, M.W., Vallance, P., Whitley, G., Foxwell, N., Moncada, S.: Platelet adhesion to human vascular endothelium is modulated by constitutive and cytokine-induced nitric oxide. Cardiovasc Res. 27:1711, 1995
59. Radomski, M.W., Palmer, R.M.J., Moncada, S.: The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br. J. Pharmacol. 92:639, 1987
60. Durante, W., Moore, E.E., Moore, F.A., Barnett, C.C.: Nitric oxide reduces endothelial expression of intercellular adhesion molecule (ICAM)-1. J. Surg. Res. 63:328, 1996
61. Gaboury, J., Woodman, R.C., Granger, D.N., Reinhardt, P., Kubes, P.: Nitric oxide prevents leukocyte adherence: role of superoxide. Am. J. Physiol. 265:H862, 1993
62. Phelps, D.T., Ferro, T.J., Higgins, P.J., Shankar, R., Parker, D.M., Kroll, M.H., Vanhoiute, P.M., Schafer, A.I.: Platelet inhibition by an l-arginine derived substance released by IL-1B-treated vascular smooth muscle cells. Am. J. Physiol. 261:H2024, 1991
63. Davenpeck, K.L., Gauthier, T.W., Lefer, A.M.: Inhibition of endo-
64. Radi, R., Beckman, J.S., Bush, K.M., Freeman, B.A.: Peroxynitrite-mediated depletion of endothelial-derived nitric oxide promotes P-selectin expression and action in rat microcirculation. Gastroenterology 107:1050, 1994
65. Fluh, W.L., Moore, E.E., Moore, F.A., Barnett, C.C.: Nitric oxide reduces endothelial expression of intercellular adhesion molecule (ICAM)-1. J. Surg. Res. 63:328, 1996
66. Inoue, S., Kawanishi, S.: Oxidative damage induced by simultaneous generation of nitric oxide and superoxide. FEBS Lett. 371:29409, 1994
67. Zingarelli, B., O’Connor, M., Wong, H., Salzman, A.L., Szabó, C.: Peroxynitrite-mediated DNA strand breakage activates poly-adeno-
nosine diphosphate ribosyl synthetase and causes cellular energy depletion in macrophages stimulated with bacterial lipopolysaccharide. J. Immunol. 156:350, 1996
68. Szabó, C., Zingarelli, B., Salzman, A.L.: Role of poly-ADP ribosyl-
transferase activation in the vascular contractile and energetic failure elicited by exogenous and endogenous nitric oxide and peroxynitrite. Circ. Res. 78:1051, 1996
69. Zingarelli, B., Salzman, A.L., Szabó, C.: Protective effects of nico-
tinamide against nitric oxide-mediated delayed vascular failure in endotoxic shock: potential involvement of poly-ADP ribosyl syn-
thease. Shock 5:258, 1996
70. Albina, J.E., Cui, S., Mateo, R.B., Reichner, J.S.: Nitric oxide-mediated apoptosis in murine peritoneal macrophages. J. Immunol. 150:580, 1993
71. Nishio, E., Fukushima, K., Shiozaki, M., Watanabe, Y.: Nitric oxide donor SNAP induces apoptosis in smooth muscle cells through cGMP-independent mechanism. Biochem. Biophys. Res. Commun. 221:163, 1996
72. Nguyen, T., Brunson, D., Crespi, C.L., Penman, B.W., Wishnok, J.S., Hurley, M., Engleberg, C., Fantone, J., Brieland, J.: Effector mech-
anisms responsible for gamma interferon-mediated host resistance to Legionella pneumophila lung infection: the role of endogenous nitric oxide differs in susceptible and resistant murine hosts. Infect. Immun. 64:5151, 1996

10. Zhu, L., Gunn, C., Beckman, J.S.: Bactericidal activity of peroxyni-
trite. Arch. Biochem. Biophys. 298:452, 1992

10. Rubbo, H., Denicola, A., Radi, R.: Peroxynitrite inactivates thiol-
containing enzymes of Trypanosoma cruzi energetic metabolism and inhibits cell respiration. Arch. Biochem. Biophys. 386:96, 1994

11. Dunn, D.L., Nelson, R.D., Condle, R.M., Simmons, R.L.: Mecha-
nisms of the adjuvant effect of hemoglobin in experimental perito-
nitis. VI. Effects of stroma-free hemoglobin and red blood cell stroma on mortality and neutrophil function. Surgery 93:653, 1983

12. Hau, T., Hoffman, R., Simmons, R.L.: Mechanism of the adjuvant effect of hemoglobin in experimental peritonitis. I. In vivo inhibition of peritoneal leukocytosis. Surgery 83:223, 1978

13. Hand, W.L.: Inhibition of cell-free oxidative bactericidal activity by erythrocytes and hemoglobin. Infect. Immun. 40:917, 1984

14. Kim, Y.M., Yamazaki, I., Piette, L.H.: The effect of hemoglobin, heamatin, and iron on neutrophil inactivation in superoxide generat-
ing systems. Arch. Biochem. Biophys. 309:308, 1994

15. Hand, W.L., King-Thompson, N.L.: Effect of erythrocyte ingestion on macrophage bactericidal function. Infect. Immun. 40:917, 1983

16. Commins, L.M., Loegering, D.J., Gudewicz, P.W.: Effect of phago-
cytosis of erythrocytes and erythrocyte ghosts on macrophage func-
tion and hydrogen peroxide production. Inflammation 14:705, 1990

17. Rioux, F., Petitclerc, E., Audet, R., Drapeau, G., Fielding, R.M., Marceau, F.: Reconvivial human hemoglobin inhibits both consti-
tutive and cytokine-induced nitric oxide-mediated relaxation of rabbit isolated aortic rings. J. Cardiovasc. Pharmacol. 24:229, 1994

18. Kim, Y.M., Hong, S.J., Billiar, T.R., Simmons, R.L.: Counterproduc-
tive effect of erythrocytes in experimental bacterial peritonitis is due to scavenging of nitric oxide and reactive oxygen intermediates. Infect. Immun. 64:3074, 1996

19. Stuehr, D.J., Marletta, M.A.: Mammalian nitrate biosynthesis: mouse macrophages produce nitrate and nitrite in response to E. coli lipopolysaccharide. Proc. Natl. Acad. Sci. U.S.A. 82:7738, 1985

20. Salvemini, D., Korbt, R., Angaard, E., Vane, J.: Immediate release of a nitric oxide-like factor from bovine aortic endothelial cells by Escherichia coli lipopolysaccharide. Proc. Natl. Acad. Sci. U.S.A. 87:2593, 1990

21. Ochoa, J.B., Udekwu, A.O., Billiar, T.R., Curran, R.D., Cerra, F.B., Simmons, R.L., Peitzman, A.B.: Nitrogen oxide levels in patients after trauma and during sepsis. Ann. Surg. 214:621, 1991

22. Evans, T., Carpenter, A., Kindermann, H., Cohen, J.: Evidence of increased nitric oxide production in patients with the sepsis syndrome. Circ. Shock. 41:77, 1993

23. Wong, H.R., Casaburi, R., Burckart, G., Shah, N., Janosky, J.E.: Increased serum nitrite and nitrate concentration in children with the sepsis syndrome. Crit. Care Med. 23:253, 1995

24. Gómez-Jiménez, J., Salgado, A., Murello, M., Cruz Martin, M., Segura, R.M., Peracaula, R., Moncada, S.: L-Arginine: nitric oxide pathway in endotoxemia and human septic shock. Crit. Care Med. 23:253, 1995

25. Ochoa, J.B., Curti, B., Peitzman, A.B., Simmons, R.L., Billiar, T.R., Hoffman, R., Rault, R., Longo, D.L., Urba, W.J., Ochoa, A.C.: Increased circulating nitrogen oxides after human tumor immunother-
apy: correlation with toxic hemodynamic changes. J. Natl. Cancer Inst. 84:864, 1992

26. Hibbs, J.B., Jr., Westenfelder, C., Taintor, R., Vavrin, Z., Kablitz, C., Baranowski, R.L., Ward, J.H., Menlove, R.L., McMurry, M.P., Kushner, J.P.: Evidence for cytokine-inducible nitric oxide synthesis from l-arginine in patients receiving interleukin-2 therapy. J. Clin. Investig. 89:867, 1992

27. Kilbourn, R.G., Rubbo, H., Gross, S.S., Griffith, O.W., Levi, R., Adams, J., Lodato, R.F.: Reversal of endotoxin-mediated shock by N\(^{\circ}\)-methyl-l-arginine, an inhibitor of nitric oxide synthesis. Bio-
chem. Biophys. Res. Commun. 172:1132, 1990

28. Thiemermann, C., Vane, J.: Inhibition of nitric oxide synthase reduces the hypotension induced by bacterial lipopolysaccharide in the rat in vivo. Eur. J. Pharmacol. 182:591, 1990

29. Meyer, J., Traber, L.D., Nelson, S., Lentz, C.W., Nakazawa, H., Herndon, D.N., Noda, H., Traber, D.L.: Reversal of hyperdynamic response to continuous endotoxin administration by inhibition of NO synthesis. J. Appl. Physiol. 73:324, 1992

30. Cobb, J.P., Natanson, C., Quaude, Z.M.N., Hoffman, W.D., Koey, C.A., Banks, S., Correll, R., Levi, R., Elin, R.J., Hosseini, J.M.: Differential hemodynamic effects of l-NAME in endotoxic shock and normal dogs. Am. J. Physiol. 268:H1634, 1995

31. Kilbourn, R.G., Gross, S.S., Rubbo, H., Adams, J., Griffith, O.W., Levi, R., Lodato, R.F.: N\(^{\circ}\)-Methyl-l-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc. Natl. Acad. Sci. U.S.A. 87:3629, 1990

32. Kilbourn, R.G., Gross, S.S., Lodato, R.F., Adams, J., Levi, R., Miller, L.L., Lachman, L.B., Griffith, O.W.: Inhibition of interleukin-1\(\alpha\)-induced nitric oxide synthase in vascular smooth muscle and full reversal of interleukin-1\(\alpha\)-induced hypotension by N\(^{\circ}\)-amino-l-argi-
nine. J. Natl. Cancer Inst. 84:1008, 1992

33. Kilbourn, R.G., Owen-Schaab, L.A., Cromeens, D.M., Gross, S.S., Flaherty, M.J., Santee, S.M., Alak, A.M., Griffith, O.W.: N\(^{\circ}\)-Methyl-
arginine: a novel treatment for endotoxin shock. Ann. Surg. 214:621, 1991

34. Johnson and Billiar: Nitric Oxide and Sepsis 195
(N\textsuperscript{4}-nitro-L-arginine methyl ester) in murine sepsis model. Arch. Surg. 130:410, 1995

141. Cobb, J.P., Natanson, C., Hoffman, W.D., Lodato, R.F., Banks, S., Koey, C.A., Solomon, M.A., Elin, R.J., Hosseini, J.M., Danner, R.L.: N\textsuperscript{4}-Amino-L-arginine, an inhibitor of nitric oxide synthase, raises vascular resistance but increases mortality rates in awake canines challenged with endotoxin. J. Exp. Med. 176:1175, 1992

142. Evans, T., Carpenter, A., Silva, A., Cohen, J.: Inhibition of nitric oxide synthase in experimental gram-negative sepsis. J. Infect. Dis. 169:343, 1994

143. Teale, D.M., Atkinson, A.M.: Inhibition of nitric oxide synthesis improves survival in a murine peritonitis model of sepsis that is not cured by antibiotics alone. J. Antimicrob. Chemother. 30:839, 1992

144. Nava, E., Palmer, R.M.J., Moncada, S.: Inhibition of nitric oxide synthase in septic shock: how much is beneficial? Lancet 338:1555, 1991

145. Laszlo, F., Whittle, B.J.R., Moncada, S.: Time-dependent enhancement or inhibition of endotoxin-induced vascular injury in rat intestine by nitric oxide synthase inhibitors. Br. J. Pharmacol. 111:1309, 1994

146. Laszlo, F., Whittle, B.J.R., Evans, S.M., Moncada, S.: Association of microvascular leakage with induction of nitric oxide synthase: effects of nitric oxide synthase in various organs. Eur. J. Pharmacol. 283:47, 1995

147. Boughton-Smith, N.K., Evans, S.M., Whittle, B.J.R., Moncada, S.: Induction of nitric oxide synthase in rat intestine and its association with tissue injury. Agents Actions 36:C125, 1993

148. Meyer, J., Lentz, C.W., Stothert, J.C., Jr., Traber, L.D., Herndon, D.N., Traber, D.L.: Effects of nitric oxide synthase inhibition in hyperdynamic endotoxemia. Crit. Care Med. 22:306, 1994

149. Nava, E., Palmer, R.M.J., Moncada, S.: The role of nitric oxide in endotoxic shock: effects of N\textsuperscript{4}-monomethyl-L-arginine. J. Cardiovasc. Pharmacol. 20(Suppl. 12):S132, 1992

150. Sorrells, D.L., Friend, C., Koltukuz, U.: Inhibition of nitric oxide with amino-o-arginine reduces bacterial translocation after endotoxin challenge in vivo. Arch. Surg. 131:1155, 1996

151. Wu, C.C., Chen, S.J., Szabo, C., Thiemermann, C., Vane, J.R.: Aminoguanidine attenuates the delayed circulatory failure and improves survival in rodent models of endotoxic shock. Br. J. Pharmacol. 114:1666, 1995

152. Szabo, C., Southan, G.J., Thiemermann, C.: Beneficial effects and improved survival in rodent models of septic shock with S-methylisothiourea sulfate, a potent and selective inhibitor of inducible nitric oxide synthase. Proc. Natl. Acad. Sci. U.S.A. 91:12472, 1994

153. Petroz, A., Bennett, D., Vallance, P.: Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 338:1557, 1991

154. Lin, P.J., Chang, C.H., Chang, J.P.: Reversal of refractory hypotension in septic shock by inhibitor of nitric oxide synthase. Chest 106:626, 1994

155. Schilling, J., Cakmakli, M., Battig, U., Geroulanos, S.: A new approach in the treatment of hypotension in human septic shock by N\textsuperscript{4}-monomethyl-L-arginine, an inhibitor of the NO synthetase. Invasive Care Med. 19:227, 1993

156. Petroz, A., Lamb, G., Leone, A., Moncada, S., Bennett, D., Vallance, P.: Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc. Res. 28:34, 1994

157. MacMicking, J.D., Nathan, C., Hom, G., Chartrain, N., Fletcher, D.S., Trumbauer, M., Stevens, K., Xie, Q.W., Sokol, K., Hutchinson, N.: Altered responses to bacterial infection and endotoxik shock in mice lacking inducible nitric oxide synthase. Cell 81:641, 1995

158. Wei, X.Q., Charles, I.G., Smith, A., Ure, J., Feng, G.J., Huang, F.P., Xu, D., Muller, W., Moncada, S., Liew, F.Y.: Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 375:408, 1995

159. Laubach, V.E., Shesely, E.G., Smithies, O., Sherman, P.A.: Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc. Natl. Acad. Sci. U.S.A. 92:10688, 1995

160. Pison, U., Lopez, F.A., Heidemeyer, C.F., Rossaint, R., Falke, K.J.: Inhaled nitric oxide reverses hypoxic pulmonary vasoconstriction without impairing gas exchange. J. Appl. Physiol. 74:1287, 1993

161. Ogura, H., Cioffi, W.G., Offner, P.F., Jordan, B.S., Johnson, A.A., Pruit, B.A., Jr.: Effect of inhaled nitric oxide on pulmonary function after sepsis in a swine model. Surgery 116:313, 1994

162. Weitzberg, E., Rudehill, A., Lundberg, J.M.: Nitric oxide inhalation attenuates pulmonary hypertension and improves gas exchange in endotoxin shock. Eur. J. Pharmacol. 233:85, 1993

163. Weitzberg, E., Rudehill, A., Alving, K., Lundberg, J.M.: Nitric oxide inhalation selectively attenuates pulmonary hypertension and arterial hypoxia in porcine endotoxin shock. Acta Physiol. Scand. 143:451, 1991

164. Kavanaugh, B.P., Mouchawar, A., Goldsmith, J., Pearl, R.G.: Effects of inhaled NO and inhibition of endogenous NO synthesis in indomethacin-induced acute lung injury. J. Appl. Physiol. 76:1524, 1994

165. Guidot, D.M., Repine, M.J., Hbertyson, B.M., Repine, J.E.: Inhaled nitric oxide prevents neutrophil mediated, oxygen radical dependent leak in isolated rat lungs. Am. J. Physiol. 269:L2, 1995

166. Guidot, D.M., Hbertyson, B.M., Kitowski, R.P., Repine, J.E.: Inhaled NO prevents IL-1-induced neutrophil accumulation and associated acute edema in isolated rat lungs. Am. J. Physiol. 272:L225, 1997

167. Rossaint, R., Falke, K.J., Lopez, F., Slama, K., Pison, U., Zapol, W.M.: Inhaled nitric oxide for the adult respiratory distress syndrome. N. Engl. J. Med. 328:399, 1993

168. Roberts, J., Polaner, D., Lang, P., Zapol, W.: Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 340:818, 1992

169. Pepe-Zaba, J., Higenbottam, T.W., Dinh-Xuan, A.T., Stone, D., Vlodvork, J.: Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 338:1173, 1991

170. Tzeng, E., Shears, L.L., II, Lotze, M.T., Billiar, T.R.: Gene therapy. Curr. Probl. Surg. 33:961, 1996

171. Kazmierski, W.M., Wolberg, G., Wilson, J.G., Smith, S.R., Williams, D.S., Thorp, H.H., Molina, L.: Iron chelates bind nitric oxide and decrease mortality in an experimental model of septic shock. Proc. Natl. Acad. Sci. U.S.A. 91:9138, 1994

172. Bune, A.J., Brand, M.P., Heales, S.J.R., Shergill, J.K., Cammack, R., Cook, H.T.: Inhibition of tetrahydrobiopterin synthesis reduces in vivo nitric oxide production in experimental septic shock. Biochem. Biophys. Res. Commun. 220:13, 1996

173. Preiser, J.C., Lejeune, P., Roman, A., Cartier, E., De Backer, D., Leeman, M., Kahn, R.J., Vincent, J.L.: Methylene blue administration in septic shock: a clinical trial. Crit. Care Med. 23:259, 1995

174. Keaney, J.F., Jr., Payana, J.C., Francis, S., Loscalzo, J.F., Stamler, J.S., Loscalzo, J.: Methylene blue reverses endotoxin-induced hypotension. Circ. Res. 74:1121, 1994

175. Giansocri, L., Alexander, J.W., Fyles, T., Fukushima, R.: Arginine-supplemented diets improve survival in gut-derived sepsis and peritonitis by modulating bacterial clearance: the role of nitric oxide. Ann. Surg. 217:644, 1993

176. Boughton-Smith, N.K., Hutcheson, I.R., Deakin, A.M., Whittle, B.J.R., Moncada, S.: Protective effect of S-nitroso-N-acetyl-penicillamine in endotoxin-induced acute intestinal damage in the rat. Eur. J. Pharmacol. 191:485, 1990

177. Pastor, C.M., Losser, M.R., Payen, D.: Nitric oxide donor prevents hepatic and systemic perfusion decrease induced by endotoxin in anesthetized rabbits. Hepatology 22:1547, 1995